Moderna stock surged 14.2% on October 9 following reports of a new NIH-backed initiative aimed at accelerating cancer vaccine development. The Therapeutic Cancer Vaccines Initiative is described as a $200 million public-private effort to coordinate clinical trials and research infrastructure, highlighting the potential for mRNA technology in personalized cancer treatments beyond infectious diseases. Despite the market enthusiasm, analysts note that the initiative's funding does not constitute direct revenue awarded to Moderna, and no immediate financial benefit has been confirmed. Consequently, investors are pricing in significant future growth based on the stock's rally, which pushed its valuation to approximately 41.3 times next-twelve-month sales, near its five-year high. The article highlights a critical upcoming catalyst for the company: a Phase 3 melanoma presentation scheduled for October 24 with partner Merck at the ESMO Congress. Strong results from this trial could support expectations for future growth, while disappointing data could challenge the current optimism reflected in Moderna's share price given its premium valuation relative to historical averages. Wall Street consensus estimates project Moderna's revenue reaching $3.39 billion by fiscal 2028, representing approximately 75% growth from 2025 levels but still less than half of its 2023 revenue. This forecast suggests a recovery path, yet the contribution from the oncology pipeline remains uncertain and is the primary variable determining whether the stock can justify its current premium multiple.